Crescent Biopharma
CBIO
47 hedge funds and large institutions have $83.1M invested in Crescent Biopharma in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 4 closing their positions.
20,760% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $5K
481% more capital invested
Capital invested by funds: $14.3M → $83.1M (+$68.8M)
325% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 4
38% more funds holding
Funds holding: 34 → 47 (+13)
0.03% more ownership
Funds ownership: 0.49% → 0.52% (+0.03%)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$821K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$584K |
| 3 |
First Manhattan
New York
|
+$463K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$308K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$197K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$397K |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$179K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$111K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$69.3K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
-$57.2K |
CBIO Hedge Fund Activity: Q4 2022 in Review
47 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2022, worth a combined $83.1M — up 481% from $14.3M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CBIO positions and 4 closed out — a net gain of 13 holders — while 7 added to existing stakes and 12 trimmed.
The largest buyer was Millennium Management, adding an estimated $821K. The largest seller was Renaissance Technologies, cutting an estimated $397K.
- 47 institutional investors held Crescent Biopharma (CBIO) as of Q4 2022, up from 34 in Q3 2022.
- Funds reported $83.1M of Crescent Biopharma stock for Q4 2022, up 481% quarter-over-quarter.
- 17 funds opened new Crescent Biopharma positions in Q4 2022 and 4 closed out, a net change of +13 holders.
- The largest Crescent Biopharma buyer in Q4 2022 was Millennium Management, an estimated $821K added.
- The largest Crescent Biopharma seller in Q4 2022 was Renaissance Technologies, an estimated $397K sold.
Based on aggregated 13F filings for Q4 2022.